These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26604182)

  • 1. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.
    Sawinski D; Kaur N; Ajeti A; Trofe-Clark J; Lim M; Bleicher M; Goral S; Forde KA; Bloom RD
    Am J Transplant; 2016 May; 16(5):1588-95. PubMed ID: 26604182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
    Kamar N; Marion O; Rostaing L; Cointault O; Ribes D; Lavayssière L; Esposito L; Del Bello A; Métivier S; Barange K; Izopet J; Alric L
    Am J Transplant; 2016 May; 16(5):1474-9. PubMed ID: 26587971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.
    Dharancy S; Coilly A; Fougerou-Leurent C; Duvoux C; Kamar N; Leroy V; Tran A; Houssel-Debry P; Canva V; Moreno C; Conti F; Dumortier J; Di Martino V; Radenne S; De Ledinghen V; D'Alteroche L; Silvain C; Besch C; Perré P; Botta-Fridlund D; Francoz C; Habersetzer F; Montialoux H; Abergel A; Debette-Gratien M; Rohel A; Rossignol E; Samuel D; Duclos-Vallée JC; Pageaux GP;
    Am J Transplant; 2017 Nov; 17(11):2869-2878. PubMed ID: 28898563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents.
    Lubetzky M; Chun S; Joelson A; Coco M; Kamal L; Ajaimy M; Gaglio P; Akalin E; De Boccardo G
    Transplantation; 2017 Jul; 101(7):1704-1710. PubMed ID: 28009781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis.
    Schrezenmeier E; Wu K; Halleck F; Liefeldt L; Brakemeier S; Bachmann F; Kron S; Budde K; Duerr M
    Am J Transplant; 2017 Mar; 17(3):819-823. PubMed ID: 27778453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
    Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
    Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.
    Zhang J; Sun W; Lin J; Tian Y; Ma L; Zhang L; Zhu Y; Qiu W
    BMC Infect Dis; 2019 Jul; 19(1):645. PubMed ID: 31324230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
    Fabrizi F; Alonso C; Palazzo A; Anders M; Reggiardo MV; Cheinquer H; Zuain MGV; Figueroa S; Mendizabal M; Silva M; Ridruejo E;
    Ann Hepatol; 2021; 25():100337. PubMed ID: 33684523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
    Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
    Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience.
    Molnar MZ; Nair S; Cseprekal O; Yazawa M; Talwar M; Balaraman V; Podila PSB; Mas V; Maluf D; Helmick RA; Campos L; Nezakatgoo N; Eymard C; Horton P; Verma R; Jenkins AH; Handley CR; Snyder HS; Cummings C; Agbim UA; Maliakkal B; Satapathy SK; Eason JD
    Am J Transplant; 2019 Nov; 19(11):3046-3057. PubMed ID: 31306549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
    Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.